Bellerophon misses primary endpoint in Phase 3 Fibrotic Interstitial Lung Disease Trial

 

• Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity

• INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-Sarcoidosis

• “The REBUILD study did not match the outcomes we saw in the exploratory Phase 2 study in this patient population; however, the overall outcome of this pivotal validation study is conclusive and we do not see a path forward for continuing the REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer.

https://finance.yahoo.com/news/bellerophon-announces-top-line-data-110000648.html